MedTrace Logo

Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection

NCT05018975 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-11-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.

Conditions

Interventions

DRUG

Tazemetostat

Tazemetostat 800mg BID PO dosing for 15 days

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Ciprian P Gheorghe, MD, PhD · Loma Linda University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-09-21
Completion
2023-09-21
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05018975 on ClinicalTrials.gov